Drug Trial Radar · NCT05673057
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Dec 29, 2022
Primary completion
May 29, 2026
Study completion Sep 14, 2026
Sponsor
- Lead sponsor
- Molecular Partners AGIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Conditions
- Leukemia
- Myeloid
- Acute
- Newly Diagnosed
Interventions
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1Drug
MP0533 is administered by intravenous infusion
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm ADrug
* MP0533 is administered by intravenous infusion * Obinutuzumab pretreatment administered
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclaxDrug
* MP0533 is administered by intravenous infusion * Azacitidine is administered by subcutaneous injection for 7 days per cycle * Venetoclax is administered orally for 14 days per cycle * Optional obinutuzumab pretreatment administered
MP0533 with Obinutuzumab pretreatmentDrug
* MP0533 is administered by intravenous infusion at densified dosing schedule * Obinutuzumab pretreatment administered
MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AMLDrug
* MP0533 is administered by intravenous infusion * Azacitidine is administered by subcutaneous injection for 7 days per cycle * Venetoclax is administered orally for 14 days per cycle * Optional obinutuzumab pretreatment administered
MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patientsDrug
* MP0533 is administered by intravenous infusion * Azacitidine is administered by subcutaneous injection for 7 days per cycle * Venetoclax is administered orally for 14 days per cycle * Optional obinutuzumab pretreatment administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 dose escalation: Recommended Phase 2 Dose Regimen and/or Maximum Tolerated Dose RegimenTime frame: from start of treatment to end of first cycle (day 1 - 28)
- Phase 2 dose extension: Overall Response RateTime frame: throughout the study (on average 3 months)
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
CHU Bordeaux
Bordeaux, France
AP-HP Hôpital Saint-Louis
Paris, France
IUCT Oncopole
Toulouse, France
Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania
Amsterdam UMC - Locatie VUmc
Amsterdam, Netherlands
Erasmus MC
Rotterdam, Netherlands
Groningen UMC
Groningen, Provincie Groningen, Netherlands
Inselspital, Universitaetsspital Bern
Bern, Canton of Bern, Switzerland
Universitaetsspital Zuerich
Zurich, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.